Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)

Technology appraisal guidance
Published: 30 June 2020
www.nice.org.uk/guidance/ta634
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advice</td>
<td>3</td>
</tr>
<tr>
<td>Information</td>
<td>3</td>
</tr>
</tbody>
</table>
Advice

NICE is unable to make a recommendation about the use in the NHS of daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma because Janssen did not provide an evidence submission. The company has confirmed that it does not intend to make a submission for the appraisal because the technology is unlikely to be a cost-effective use of NHS resources.

Information

If NHS organisations wish to consider daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3724-0

Accreditation

NICE accredited

www.nice.org.uk/accreditation